The aim of this study is to identify patients with DM at high risk of CVD using elevated
N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (>125pg/mL), and (2) intensify
therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose
co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this
high-risk DM population.
Phase:
Phase 4
Details
Lead Sponsor:
National Heart Centre Singapore
Collaborators:
Mackay Memorial Hospital Medanta, The Medicity, India National Taiwan University Hospital Peking University People's Hospital Public Health Foundation of India Putrajaya Hospital, Malaysia Singapore General Hospital Universiti Teknologi Mara